Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE-ACT
NCT07191145Phase 3Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eptinezumab in post-traumatic headache (PTH), sponsored by Sunnybrook Health Sciences Centre. Started Nov 2026; status: recruiting.
02
Drugs
eptinezumab
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT07191145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191145.